TRAIL receptor-targeted therapy.
TRAIL receptor-targeted therapy.
复制标题
DOI：
10.2217/14796694.2.4.493
复制
发表时间：
2006-08-01
期刊：
影响因子：
--
通讯作者：
Lobuglio, Albert F
中科院分区：
文献类型：
--
作者：
Buchsbaum, Donald J;Zhou, Tong;Lobuglio, Albert F
肿瘤坏死因子 (TNF) 相关凋亡诱导配体 (TRAIL) 是 TNF 细胞因子家族的成员。基于其在多种癌细胞系和人类肿瘤异种移植物中选择性诱导细胞凋亡的能力，TRAIL 已作为癌症治疗的潜在生物制剂进行药物开发。多种化疗药物已被证明可以增强 TRAIL 的细胞毒性作用。 TRAIL 作为抗癌疗法的潜在益处已通过其增强放射疗法疗效的能力得到进一步表明。临床前研究表明，选择性结合 TRAIL 死亡受体的激动性单克隆抗体在癌症治疗中具有潜在用途。本综述概述了 TRAIL 受体介导的肿瘤细胞凋亡，仅使用 TRAIL 或激动性单克隆抗体或使用化疗药物。讨论了用这些配体单独或与化疗或放疗联合治疗肿瘤异种移植物，以及有关早期临床试验的初步信息。需要在联合治疗方案中使用 TRAIL 受体配体进行额外的临床试验，以确定它们用于癌症靶向治疗的潜力。
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines. Based on its ability to induce apoptosis selectively in a wide variety of cancer cell lines and human tumor xenografts, TRAIL has been in drug development as a potential biological agent for cancer therapy. A variety of chemotherapy agents have been shown to enhance the cytotoxic effects of TRAIL. The potential benefits of TRAIL as an anticancer therapy have been further indicated by its ability to enhance the efficacy of radiotherapy. Preclinical studies have shown the potential use of agonistic monoclonal antibodies that selectively bind TRAIL death receptors for cancer therapy. This review provides an overview of TRAIL receptor-mediated apoptosis of tumor cells, with TRAIL or agonistic monoclonal antibodies only or with chemotherapy drugs. Treatment of tumor xenografts with these ligands, alone or in combination with chemotherapy or radiation, are discussed along with preliminary information about early clinical trials. Additional clinical trials with TRAIL receptor ligands in combination treatment regimens are required to determine their potential for targeted therapy of cancer.